Home
Career Stage
Medical Students Residents Attendings CPT Codes Resources Blog Support

J1411 Injection, hemgenix, per treatment dose

J Codes (Drugs)

Also known as: hemgenix, eteplirsen gene therapy

Hemgenix (eteplirsen) injection, per treatment dose. A gene therapy administered by intravenous infusion for hemophilia B treatment.

In Plain Language

hemophilia B gene therapy; blood clotting gene treatment

Clinical Context

Used for hemophilia B (Factor IX deficiency) in patients with severe disease. Gene therapy designed to provide sustained Factor IX production. Single infusion can provide long-term correction of Factor IX deficiency.

RVU Information

CPT J1411 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.

Billing & Documentation

J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.

Specialties

HematologyHemophilia ClinicGenetics

Frequently Asked Questions

What is CPT code J1411?

CPT J1411 (Injection, hemgenix, per treatment dose) is a J Codes (Drugs) code. Hemgenix (eteplirsen) injection, per treatment dose. A gene therapy administered by intravenous infusion for hemophilia B treatment.

How is J1411 administered?

CPT J1411 is administered by a healthcare provider, typically via injection or infusion. Used for hemophilia B (Factor IX deficiency) in patients with severe disease. Gene therapy designed to provide sustained Factor IX production. Single infusion can provide long-term correction of Factor IX deficiency. It is used by Hematology, Hemophilia Clinic, Genetics.

When is CPT J1411 used?

Used for hemophilia B (Factor IX deficiency) in patients with severe disease. Gene therapy designed to provide sustained Factor IX production. Single infusion can provide long-term correction of Factor IX deficiency.

Track This Code in RVU Edge

Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.

CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.